Metabolic Inflammation-Associated IL-17A Causes Non-alcoholic Steatohepatitis and Hepatocellular Carcinoma - PubMed (original) (raw)
. 2016 Jul 11;30(1):161-175.
doi: 10.1016/j.ccell.2016.05.020.
Affiliations
- PMID: 27411590
- DOI: 10.1016/j.ccell.2016.05.020
Free article
Metabolic Inflammation-Associated IL-17A Causes Non-alcoholic Steatohepatitis and Hepatocellular Carcinoma
Ana L Gomes et al. Cancer Cell. 2016.
Free article
Abstract
Obesity increases hepatocellular carcinoma (HCC) risks via unknown mediators. We report that hepatic unconventional prefoldin RPB5 interactor (URI) couples nutrient surpluses to inflammation and non-alcoholic steatohepatitis (NASH), a common cause of HCC. URI-induced DNA damage in hepatocytes triggers inflammation via T helper 17 (Th17) lymphocytes and interleukin 17A (IL-17A). This induces white adipose tissue neutrophil infiltration mediating insulin resistance (IR) and fatty acid release, stored in liver as triglycerides, causing NASH. NASH and subsequently HCC are prevented by pharmacological suppression of Th17 cell differentiation, IL-17A blocking antibodies, and genetic ablation of the IL-17A receptor in myeloid cells. Human hepatitis, fatty liver, and viral hepatitis-associated HCC exhibit increased IL-17A correlating positively with steatosis. IL-17A blockers may prevent IR, NASH, and HCC in high-risk patients.
Copyright © 2016 Elsevier Inc. All rights reserved.
Comment in
- P(URI)fying Novel Drivers of NASH and HCC: A Feedforward Loop of IL17A via White Adipose Tissue.
Weber A, Heikenwalder M. Weber A, et al. Cancer Cell. 2016 Jul 11;30(1):15-17. doi: 10.1016/j.ccell.2016.06.010. Cancer Cell. 2016. PMID: 27411585 - From NAFLD to HCC: Is IL-17 the crucial link?
Hatting M, Tacke F. Hatting M, et al. Hepatology. 2017 Feb;65(2):739-741. doi: 10.1002/hep.28934. Epub 2016 Dec 24. Hepatology. 2017. PMID: 28012256 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases